Holen Sie sich die Stockscreener-App
4.065
0.37%
0.015
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock - Stock Titan
Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) CFO converts RSUs into 2,985 common shares - Stock Titan
[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Plus Therapeutics provides mid-year business update including corporate rebranding - MSN
Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress - marketscreener.com
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - Yahoo Finance
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY - Investing.com
From Plus to Cerenome: A New Identity for an Integrated CNS Cancer Strategy - BriefGlance
Price to earnings forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Price to sales forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to revenue forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Index - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Growth Benchmark - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell Microcap Index - marketscreener.com
Plus Therapeutics, Inc. Actuals & Estimates (DUS:XMP1) - TradingView
XMP1 Forecast — Price Target — Prediction for 2027 - TradingView
Plus Therapeutics, Inc. Actuals & Estimates (GETTEX:XMP1) - TradingView
Plus Therapeutics, Inc. Actuals & Estimates (FWB:XMP1) - TradingView
Plus Therapeutics, Inc. Actuals & Estimates (NASDAQ:PSTV) - TradingView
CNSide signs coverage deal with Elevance Health for 45.4M - Investing.com UK
Plus Therapeutics wins Elevance Health coverage deal - MSN
PSTV Forecast — Price Target — Prediction for 2027 - TradingView
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
Plus Therapeutics Subsidiary CNSide Diagnostics Signs National Coverage Agreement with Elevance Health for CNSide CSF Tumor Cell Enumeration Assay - Quiver Quantitative
Plus Therapeutics Secures National Coverage Agreement with - GlobeNewswire
Plus Therapeutics (PSTV) reports Q1 loss, tops revenue estimates - MSN
Plus Therapeutics to Provide Business Update Call on June 30, 2026 - Sahm
Plus Therapeutics to detail CNSide launch, Reyobiq plan June 30 - Stock Titan
Plus Therapeutics Inc (PSTV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PSTV Should I Buy - Intellectia AI
Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Plus Therapeutics Inc (PSTV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Plus Therapeutics Inc (PSTV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Plus Therapeutics Inc (PSTV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Plus Therapeutics Inc (PSTV) Institutional Confidence - TradingKey
Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Plus Therapeutics Inc (PSTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Plus Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Plus Therapeutics Is Maintained at Buy by Ascendiant Capital - Moomoo
PSTV Maintained by Ascendiant Capital -- Price Target Lowered to $57.00 - GuruFocus
[EFFECT] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Plus Therapeutics Launches New At-The-Market Equity Program - The Globe and Mail
PLUS THERAPEUTICS, INC. Files Form 8-K with SEC Detailing Material Definitive Agreement – June 2026 - Minichart
Plus Therapeutics Launches $17.35 Million ATM Equity Program With Canaccord Genuity - TradingView
Plus Therapeutics (NASDAQ: PSTV) sets $17,350,000 at-the-market stock program - Stock Titan
Plus Therapeutics (PSTV) adds Form of Indenture to S-3/A filing - Stock Titan
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform - Yahoo Finance
CNSide Diagnostics receives laboratory accreditation from CAP By Investing.com - Investing.com Nigeria
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory - The Manila Times
CNSide Diagnostics, a Plus Therapeutics Subsidiary, Achieves Prestigious CAP Accreditation for Clinical Laboratory - Quiver Quantitative
Plus Therapeutics (NASDAQ: PSTV) launches $17.35M ATM with Canaccord - Stock Titan
Plus TherapeuticsMay Offer And Sell Up To $100 Million Of Securities From Time To TimeSEC Filing - TradingView
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
1.95%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):